Assess whether to resubmit, meet, or pause the program after an AdCom

SITUATION After an AdCom briefing document that overstates subgroup findings, inspection-readiness findings at a CMO is the working evidence for pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT. Decide whether to resubmit, meet, or pause the program using only what inspection-readiness findings at a CMO actually supports.

DECISION Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose To resubmit, meet, / Pause the program using inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; inspection-readiness findings at a CMO already has the discriminator after an AdCom briefing document that overstates subgroup findings. 2. Keep Pause the program in force until inspection-readiness findings at a CMO is completed after an AdCom briefing document that overstates subgroup findings for pediatric-plan strategist. 3. Treat inspection-readiness findings at a CMO as To resubmit, meet, because both readings appear after an AdCom briefing document that overstates subgroup findings. 4. Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the decision to resubmit, meet, or turns on in inspection-readiness findings at a CMO.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read inspection-readiness findings at a CMO against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to resubmit, meet, or for pediatric-plan strategist.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings). If inspection-readiness findings at a CMO cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent missing evidence an RWE group proposing a post-marketing study instead of a new RCT does not have.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in inspection-readiness findings at a CMO, then the action for pediatric-plan strategist - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - FDA Response and Labeling finding in inspection-readiness findings at a CMO that a second reviewer can re-perform - Missing page in inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings, if any